Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
James R. Downing, M.D., becomes hospital’s sixth IOM member
The Pediatric Cancer Genome Project uncovers the genetic mutations that give rise to cancer.
Pediatric Cancer Genome Project scientists begin to uncover treasures.
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. (Dr. James Downing)
For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.
The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps, according to new findings from St. Jude Children’s Research Hospital.
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death.
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
Scientists have identified genetic mutations that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).
Scientists at St. Jude have identified distinctive genetic changes that cause relapse in children with acute lymphoblastic leukemia (ALL).
An electron microscope uses a beam of electrons to produce highly detailed images that reveal a specimen’s structure and composition. The new instrument, one of only 200 of its type in the world, is the centerpiece of a recent expansion of cellular imaging at St. Jude.
St. Jude researchers have discovered evidence that a series of genetic mutations work together to initiate most cases of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL). These findings provide new avenues to pursue to gain a better understanding of these disease processes and, ultimately, to develop better therapies.
When James Downing walked into his pathology lab one day, postdoctoral fellow Charles Mullighan was staring at his computer screen, transfixed. "He was literally white," Downing recalls. "You are not going to believe what I just found," Mullighan said.
The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to St. Jude investigators.
Investigators at St. Jude have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia, the most common cancer in children.
Former St. Jude Director Arthur W. Nienhuis, M.D., and George Simon, chair of the St. Jude Board of Governors, recently announced that William E. Evans, Pharm.D., assumed the position of St. Jude Director and CEO. Nov. 1, 2004.
James Downing, MD, has been named St. Jude Scientific Director. Downing, who will continue serving as Pathology chair, is looking forward to working more closely with researchers and hospital leaders throughout the institution.
The research of James Downing, MD, Pathology, is featured in the October 31 issue of Bio-IT World.